We continue to help families affected by Zoloft birth defects.

Zoloft Lawsuit Information

Our lawyers are accepting and aggressively litigating nationwide Zoloft Lawsuit claims to collect damages for Zoloft birth defects.

Have you or a loved one taken Zoloft or another SSRI during pregnancy and given birth to a child with a heart defect or other birth defect? If this is the case, you may be entitled to file a Zoloft Lawsuit claim to collect money damages. Call us now at 800-845-6913 or click this link for Zoloft Lawsuit Information.

Zoloft and other SSRI antidepressant drugs have been linked to several birth defect side effects that may affect a child’s heart, lungs, brain, spine, facial area, skeletal frame and abdominals.

One of the major heart defect linked to use of Zoloft and SSRI’s during pregnancy is persistent pulmonary hypertension of the newborn (PPHN).

Some of the other specific types of birth defects that have been linked to taking Zoloft while pregnant include clubfoot, anal atresia, atrial septal defect (ASD), ventricular septal defect (VSD), hypoplastic left heart syndrome (HLHS), and craniosynostosis.

Let our nationwide Zoloft attorneys help you recover the compensation you and your child deserve.

A link between Actos (generic pioglitazone) and bladder cancer first was identified during preclinical animal studies and was reported on the drug’s warning label in 1999. At the time, it was thought that the bladder cancer risk might be specific to rats. Then, a human study also showed a link. In September 2010, the FDA announced an ongoing investigation of the possible bladder cancer risk to humans. Drug maker Takeda launched a 10-year investigation to study the long-term risk of bladder cancer linked to Actos. In June 2011, a study published in the medical journal Diabetes Care concluded that prolonged Actos use by diabetes patients is linked to an increased risk of bladder cancer.

Actos Bladder Cancer Lawsuit Attorneys

If you or a loved on was diagnosed with bladder cancer after taking the diabetes drug Actos, you may be entitled to recover financial compensation. Contact us now to for a free no-obligation consultation with an experienced Actos bladder cancer lawsuit attorney.

Use the diabetes drug lawsuit attorney contact request form on this page or call us toll-free at 800-845-6913.

Let us help you recover the financial compensation you deserve.

GlaxoSmithKline (GKS) has entered into a settlement agreement to pay the U.S. government $3 billion to resolve several civil and criminal investigations into the drug company.

The settlement will cover the Justice Department investigation into GSK’s development and marketing of its controversial diabetes drug Avandia, which has been linked to increased risks of heart attack, stroke, congestive heart failure (CHF), and sudden cardiac death. It also covers allegations that GSK defrauded the Medicaid program and marketed some of its drugs illegally.

The settlement relates to an eight-year-old government investigation into Glaxo’s marketing and sales of several prescription drugs, including Wellbutrin and SSRI antidepressant Paxil between 1997 and 2004. Issues included how Glaxo represented Paxil suicide risks and whether Glaxo promoted off-label uses for Wellbutrin. Government investigators also examined medical education and drug trials funded by Glaxo as well ways the company potentially influenced doctors.

The final terms of the settlement are still being negotiated. GSK expects to pay the U.S. government in 2012.

The $3 billion settlement “is a significant step toward resolving difficult, longstanding matters which do not reflect the company that we are today,” Glaxo CEO Andrew Witty said in a statement. “In recent years, we have fundamentally changed our procedures for compliance, marketing and selling in the U.S. to ensure that we operate with high standards of integrity and that we conduct our business openly and transparently.”

Glaxo’s full statement may be viewed here.

The attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases.

GlaxoSmithKline argued that the time limits set out in the statutes of limitation began to run in May 2007, when a study was published in the New England Journal of Medicine linking Avania use to an increased risk of heart problems.  The Court rejected GSK’s argument and ruled that under Pennsylvania’s “discovery rule” the statute of limitations doesn’t begin to run until the injured party knew or should have known that their injury was caused by Avandia side effects.

Attorneys for the people who filed the lawsuits claimed that they neither knew nor should have known until late in the summer of 2010 that the injuries from which they suffer were caused by the diabetes drug.  They claimed that they were not aware of Avandia heart risk information before then.

In her Order dated September 7, 2011, U.S. District Judge Cynthia M. Rufe ruled that, “There is certainly a point at which a reasonable person was on notice to investigate the possibility of a connection between an injury and use of Avandia, but the Court cannot, on the present record, determine that point to be May 21, 2007.”

Almost a year ago, on September 23, 2010, the FDA severely restricted Avandia use in the U.S..  The drug now is available to new patients, “only if they are unable to achieve glucose control on other medications and are unable to take Actos (pioglitazone), the only other drug in this class.” The same day, an Avandia recall in europe was announced by the European Medical Agency (EMA).  The EMA Avandia recall was ordered after it concluded that more severe restrictions would not adequately protect patients from the drug’s increased heart risks.

The FDA Avandia restrictions were ordered in response to overwhelming data linking the Type 2 diabetes medication (generic name “rosiglitazone”) to an increased risk of cardiovascular events, including stroke, heart attack, congestive heart failure (CHF), and sudden cardiac death.

Avandia Lawsuit 2011 :  Settlement Claim Time Limits

The attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases.

Diabetes drug maker GlaxoSmithKline has agreed to pay more than $700 million to settle about 12,000 Avandia lawsuit claims.  The lawsuits allege that  GSK failed to warn patients about the diabetes drug’s increased stroke and heart attack risk.   Several studies have linked Avandia use to an increased risk of heart attack, stroke, and congestive heart failure.

Avandia settlements in more than 1,000 case are expected soon according to an Avandia attorney representing plaintiffs on cases in Illinois, California, and Pennsylvania.  Settlement talks in California already have resulted in 2,400 Avandia claims being resolved.  Avandia settlement amounts vary depending on the specific facts relating to the personal injury or wrongful death damages suffered in each case.

An Avandia recall in Europe was announced last September.  The FDA fell short of ordering an Avandia recall, but issued tight new restrictions on the diabetes medication.  Once the world’s best-selling diabetes drug,  Avandia sales topped $3.2 billion in 2006.  Glaxo has said that it no longer would promote the drug.

2011 Avandia Settlement Claims

The attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases.

Researchers reviewed data from previously published observational studies that compared the “cardiovascular outcomes” of about 810,000 type 2 diabetes patients who used Avandia or Actos. Among the diabetics, Avandia use of was linked to significantly higher odds of heart attack (myocardial infarction), and death compared to use of Actos. The research suggests that for every 100,000 patients who take Avandia rather than Actos, there could be 170 more heart attacks, 649 more cases of congestive heart failure, and 431 more deaths.

First approved in 1998, Avandia once was touted as a “miracle drug” to treat type 2 diabetes. In 2007, a study was published in the new England Journal of Medicine linking Avandia use to increased heart risks and cardiovascular death. In response, a “black box” warning was added to Avandia and increasing calls for an Avandia recall in the U.S. were resisted by the drug’s manufacturer, GlaxoSmithKline. On September 23, 2010, the FDA fell short of an Avandia recall, but severely restricted use of the diabetes drug.

Avandia lawsuits continue to filed in 2011 to recover financial compensation for heart problems suffered after taking the controversial diabetes drug. GSK has agreed to pay hundreds of millions of dollar to settle Avandia lawsuits.

2011 Avandia Lawsuits

The attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases.

Attorney General Caldwell issued the following statement about the Avandia lawsuit:

“I am committed to pursuing those who prey on our citizens and our state Medicaid program. This type of exploitation jeopardizes our economy, our health and in some cases our lives. Our focus on these perpetrators sends a message of zero tolerance for such fraud and abuse.”

The LA Attorney General’s office is working closely with the Department of Health and Hospitals on the case.  DHH Secretary Bruce D. Greenstein also issued a statement:

“I welcome Attorney General Caldwell’s tough stance in helping us protect precious Medicaid dollars. It is terribly disturbing that a company this size would take advantage of people by offering misleading information and take funds away from those who need it most. We are committed to rooting out abuse and misuse of Medicaid money wherever it occurs and to working with the Attorney General to ensure accountability for those who prey on the system.”

The lawsuit seeks to recover compensation for the more than $36 million in Avandia reimbursements paid by the Louisiana Medicaid program to GlaxoSmithKline. The lawsuit claims that GSK fraudulently induced the Avandia reimbursements. The case is civil action for civil fines, civil penalties, restitution and other monetary relief.

Avandia Settlements

The attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases.

Drug regulators at the U.S. FDA have fallen short of ordering an Avandia recall.  The FDA decided in 2010 to allow Avandia to remain on the market with more severe restrictions and stronger warnings.  Avandia has been removed from the European market.

Avandia, generic name Rosiglitazone, was approved by the FDA to treat Type 2 diabetes in 1998.  Gross annual sales of Avandia in peaked in 2006 at more than $3 billion.

In 2007, a study published in the New England Journal of Medicine found that Avandia heart attack risk was significantly greater than that of other diabetes drugs.  The study also found a link between Avandia use and a significantly increased risk of sudden cardiovascular death.  In response, the FDA added “black box” warning to Avandia.  Drug safety advocates called for an Avandia recall.

Avandia lawsuits were filed across the United States claiming that drug maker GlaxoSmithKline failed to warn diabetes patients and doctors of Avandia heart attack risks.  2011 Avandia settlements have been reached in thousands of cases.  2011 Avandia lawsuits continue to be filed across the United States.

Avandia Settlement Claims : Heart Attack Cases

If you or someone you love suffered a heart attack after taking Avandia, you may be entitled to financial compensation and should contact an Avandia attorney right away.

Time is limited to file an Avandia lawsuit.

Act now to start your Avandia settlement claim.

Submit the online attorney contact request form for a free, no-obligation consultation with a top Avandia lawsuit attorney.

The settled lawsuit claimed that Avandia’s dangerous side-effects increase the risk of heart attack and death, that Glaxo failed to adequately warn consumers or the medical community about the risk. The legal claims against Glaxo include negligence, breach of warranty, strict product liability (failure to warn), unfair trade practices (fraud) and infliction of emotional distress.

In 2006, the worldwide sales of Avandia topped $3.2 billion. In 2007, a study was published in the New England Journal of Medicine that link use of Avandia to a 43% increase in the risk of heart attack and a 64% increase in the risk of death from cardiovascular causes. Sales if the diabetes drug plummeted to about $1.2 billion in 2009. On September 23, 2010, the FDA announced tight new restrictions on Avandia, but fell short of ordering an Avandia recall. The same day, it was announced that the drug would be pulled from the market in Europe. Glaxo has stopped promoting Avandia and sales of the diabetes drug are expected to drop to “insignificant” levels.

On January 17, 2011, GlaxoSmithKline announced a $3.4 billion legal charge against earnings in the 4th quarter of 2011.

“We recognize that this is a significant charge, but we believe the approach we are taking to resolve long-standing legal matters is in the company’s best interests,” said Glaxo’s senior vice president for global litigation. “We have closed out a number of major cases over the last year and we remain determined to do all we can to reduce our litigation risk.”

More Avandia settlements are expected this year.

Avandia settlement claims time limits

The attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases.

The first trial of an Avandia lawsuit is scheduled to begin on January 24 in Philadelphia, PA. The lawsuit was filed by the family of James Buford, a man who died of a heart attack in 2006 at the age of 49 while taking Avandia (rosiglitazone) to control his diabetes. The case seeks both compensatory and punitive damages. The lawsuit claims that Mr. Buford’s death was the result of Glaxo’s failure to warn doctors, patients and the FDA of Avandia heart risks.

Attorneys allege that GSK tried to conceal Avandia heart attack risks and intentionally misrepresented information about Avandia side effects. In addition, lawyers for the Buford’s claim that Glaxo attempted to intimidate doctors and scientists who raised questions about the safety of the diabetes drug.

GSK faces thousands more Avandia lawsuits across the United States involving similar claims.

Do I qualify for an Avandia settlement?

Avandia lawsuits seek financial compensation for heart attack, stroke and congestive heart failure side effects. If you or a loved one had a heart attack or stroke after taking Avandia, or was diagnosed with CHF, you may qualify for an Avandia settlement and should contact a lawyer immediately to discuss your options by submitting the case evaluation request form on the right side of this page. Get Legal Help Now.

Is there still time to file an Avandia lawsuit?

The attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases.